|Bid||1.7000 x 100|
|Ask||1.7300 x 200|
|Day's Range||1.7000 - 1.7200|
|52 Week Range||1.4700 - 4.6900|
|PE Ratio (TTM)||-2.09|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Imprimis Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Imprimis Pharmaceuticals, Inc. – Akorn, Inc., Antares Pharma, Inc., Retractable Technologies, Inc., Delcath Systems, Inc., ICU Medical, Inc. and Tandem Diabetes Care, Inc. (AKRX-US, ATRS-US, RVP-US, DCTH-US, ICUI-US ... Read more (Read more...)
On a per-share basis, the San Diego-based company said it had net income of 6 cents. The pharmaceutical and drug compounding company posted revenue of $6.9 million in the period. In the final minutes of ...
A curcumin emulsion for injection made by compounding pharmacy ImprimisRx contained a dangerous impurity. The company formulates a variety of questionable products for intravenous use and pays a popular naturopathic doctor as a consultant.